Biomedicine & Pharmacotherapy (Nov 2020)

Diacerein: Recent insight into pharmacological activities and molecular pathways

  • Maged Almezgagi,
  • Yu Zhang,
  • Kamal Hezam,
  • Emad Shamsan,
  • Mohammed Gamah,
  • Fadhl Al-shaebi,
  • Abdul Baset Abbas,
  • Muhammad Shoaib,
  • Bassam Saif,
  • Ying Han,
  • Ruhan Jia,
  • Wei Zhang

Journal volume & issue
Vol. 131
p. 110594

Abstract

Read online

Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) and the active metabolite is rhein. It is a non-steroidal anti-inflammatory drug with unique pharmacological properties as anti-oxidant and anti-apoptosis. Diacerein has recently shown to have a potential role by mediating anti-inflammatory as well as anti-oxidant and anti-apoptosis in kidney injury, diabetes mullites, and a beneficial effect on pain relief. It may have a therapeutic role in cancer, ulcerative colitis, testicular injury and cervical hyperkeratosis. Furthermore, diacerein has a valuable addition in combination therapy as a synergetic agent. This review, the first of its kind, highlights the proposed roles of diacerein in osteoarthritis and discusses recent results supporting its emerging roles with a particular focus on how these new insights may facilitate the rational development of diacerein for targeted therapies in the future.

Keywords